NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

521.95 -1.75 (-0.33%)

Near 52W Low of ₹498.45

158.5K NSE+BSE Volume

NSE 23 Dec, 2025 2:44 PM (IST)

22,783.1

Market Cap

Below industry Median

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

29 Oct 2016

521.95

-0.33%

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales and PAT have grown at a CAGR of 18.4% and 23.2% respectively (FY08-13). Geographical breakup of sales: North (29%), West (27%), South (23%) and East (21%). Export contributes ~10.4% of total revenue. Company...

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

28 Oct 2016

521.95

-0.33%

Emami - 2QFY17 Result Update

Buy: Emami Ltd.

Reliance Securities

Emami has posted 10.2% yoy growth in consolidated sales to Rs5.8bn in 2QFY17. While its EBITDA grew 15.3% yoy to Rs1.7bn, reported PAT rose by 9.2% yoy to Rs661mn. Volume grew by robust 10% yoy which is impressive considering current market scenario marked with weaker demand. Volume growth excluding Kesh King stood at 6% in 2Q. Expecting 17.5% revenue and 19.4% earnings CAGR through FY16-18E, we maintain our BUY recommendation on the stock with an upwardly...

Emami Ltd.'s price crossed above 30Day SMA today

Emami Ltd.

05 Aug 2016

521.95

-0.33%

EARNINGS UPDATE- EMAMI LTD.

Buy: Emami Ltd.

Chola Wealth Direct

Emami Ltd. is trading below all available SMAs

Emami Ltd.

04 Aug 2016

521.95

-0.33%

Emami Q1FY17 Update 4Aug2016

Neutral: Emami Ltd.

Target

Phillip Capital

High interest costs and goodwill amortisation led to decline in reported PAT Key highlights: In Q1FY17, organic sales grew by 9.4% (6.4% volume growth). Strong growth was driven by BoroPlus/healthcare/cooling oils/cooling talc which grew by 38%/14%/8%/15% yoy. However, growth was lacklustre in Fair & Handsome/balms, which grew by 1%/6%. Domestic/international/CSD businesses grew 21%/14%/12%. Sales of Kesh...

Emami Ltd. is trading below all available SMAs

Emami Ltd.

03 Aug 2016

521.95

-0.33%

Emami: Double-digit volume growth likely in FY17

Buy: Emami Ltd.

Motilal Oswal

Domestic sales grew 21% YoY in 1QFY17, with HMN gaining market share across its key categories. International business and CSD segment posted sales growth of 14% and 12% YoY, respectively. Gross margin stood at 64.5% (up 390bp YoY). Higher A&P; spends (up 70bp YoY to 23.8%) were partially offset by lower other expenses (down 120bp YoY to 8.6%). EBITDA margin expanded 450bp YoY to 22.9% (est. of +40bp YoY), mainly due to gross margin improvement. EBITDA thus grew 49.2% (est. of +22.8%) to INR1.5b. Adjusted PAT grew 18.4% (est. of +7.1%) to INR 1.2b....

Emami Ltd. is trading below all available SMAs

Emami Ltd.

03 Aug 2016

521.95

-0.33%

Emami - 1QFY17 Result Update

Buy: Emami Ltd.

Reliance Securities

Mixed Growth Trend but Margins Remain Robust Emami posted consolidated revenues of Rs6.4bn in 1QFY17, a yoy growth of 19.9%. While consolidated EBITDA grew 49.1% to Rs1.5bn, Consolidated cash profits for the quarter increased 17.5% to Rs1.3bn. Organic growth was recorded at 9.5% yoy with organic volume growing by 6.4% yoy. Reported numbers have been impacted on account of acquisition of Kesh King towards 1QFY16-end and resultant amortisation of the brand. Expecting Emami to report revenue and earnings CAGR of 17.5% & 20.9% through FY16-18E on the back of recovery in...

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Is Emami Ltd. worth buying?

233 Votes:

Buy 74.25%

Sell 17.6%

Hold 8.15%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf